

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

WinNonlin

RRID:SCR_024504

Type: Tool

Proper Citation

WinNonlin (RRID:SCR_024504)

Resource Information

URL: <https://www.certara.com/software/phoenix-pkpd/>

Proper Citation: WinNonlin (RRID:SCR_024504)

Description: Software to automate repetitive analysis steps and is widely considered the industry standard for NCA, TK, and PK/PD modeling. Used as non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling tool.

Synonyms: Phoenix WinNonlin

Resource Type: software application, software resource

Keywords: automate repetitive analysis steps, NCA, TK, PK/PD modeling, non-compartmental analysis, pharmacokinetic/pharmacodynamic, toxicokinetic, modeling tool,

Resource Name: WinNonlin

Resource ID: SCR_024504

Record Creation Time: 20231002T161336+0000

Record Last Update: 20260727T040822+0000

Ratings and Alerts

No rating or validation information has been found for WinNonlin.

No alerts have been found for WinNonlin.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1804 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Zhang CX, et al. (2026) Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis. *Clinical and translational science*, 19(1), e70453.

Lisbon EA, et al. (2026) Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients. *Clinical pharmacology and therapeutics*, 119(1), 120.

Hunt HJ, et al. (2026) Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in Nonclinical and Clinical Studies. *Journal of clinical pharmacology*, 66(1), e70113.

Röth A, et al. (2026) Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. *American journal of hematology*, 101(2), 242.

Etkins J, et al. (2026) Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. *Clinical and translational science*, 19(1), e70455.

Azzopardi D, et al. (2026) A Randomized Crossover Clinical Study to Assess the Effect of Oral Nicotine Pouches Used for Different Durations on Plasma Nicotine Pharmacokinetics in Healthy Oral Pouch Consumers. *Journal of clinical pharmacology*, 66(1), e70090.

Li C, et al. (2025) Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 × PD-L1 Antibody-Drug Conjugate. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3581.

Xue J, et al. (2025) An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques. *Cell reports*, 44(9), 116228.

Esdar C, et al. (2025) M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer. *Molecular cancer therapeutics*, 24(7), 1040.

Colevas AD, et al. (2025) First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 815.

Srinivasan S, et al. (2025) Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3662.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 965.

Hu L, et al. (2025) HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study. *Med (New York, N.Y.)*, 6(6), 100575.

Siu LL, et al. (2025) AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(8), 1449.

Alqaisi HA, et al. (2025) Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 993.

Green AL, et al. (2025) Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(9), 1587.

Natale CA, et al. (2025) LNS8801: An Enantiomerically Pure Agonist of the G Protein-Coupled Estrogen Receptor Suitable for Clinical Development. *Cancer research communications*, 5(4), 556.

Xue J, et al. (2025) Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with Locally Advanced or Metastatic Epithelial Tumor: Results from first-in-human phase I/Ib study. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Hamid O, et al. (2025) First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(19), 4089.

Kummar S, et al. (2025) First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies. *Cancer research communications*, 5(1), 94.